ABSI
Absci·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Buy"
Gap Down
EPS Beats Expectation
RSI Oversold
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ABSI
Absci Corporation
A drug and target discovery company that harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins
18105 SE Mill Plain Blvd, Vancouver, WA 98683
--
Absci Corporation was incorporated as a limited liability company in Oregon in August 2011. The company is a data-first generative AI drug creation company that combines AI with scalable wet laboratory technology to create better biologics for patients at a faster rate.
Earnings Call
Q2/2025
Estimate EPS-0.21
Actual EPS-0.24
Estimate Revenue1.35M
Actual Revenue600.00K
Absci's Q2 2025 Earnings Call: Unraveling Key Contradictions in Revenue Recognition, Dosing Strategies, and Clinical Timelines
Aug 13,2025 12:30
Earnings Decrypt
Earnings Decrypt
Q1/2025
Estimate EPS-0.22
Actual EPS-0.21
Estimate Revenue1.07M
Actual Revenue1.18M
Absci's Q1 2025: Key Contradictions in Pipeline Development and Partnership Strategy
May 20,2025 03:44
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ABSI has released its 2025 Q2 earnings. EPS was reported at -0.24, versus the expected -0.21, missing expectations. The chart below visualizes how ABSI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ABSI has released its 2025 Q2 earnings report, with revenue of 593.00K, reflecting a YoY change of -53.31%, and net profit of -30.57M, showing a YoY change of -23.51%. The Sankey diagram below clearly presents ABSI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
